| P50 | author | Jesus M Banales | Q64913476 |
| P2093 | author name string | Bing Huang | |
| | Nicholas F Larusso | |
| | Vicente E Torres | |
| | Marie C Hogan | |
| | Tatyana V Masyuk | |
| | Anatoliy I Masyuk | |
| | Sergio A Gradilone | |
| | Angela J Stroope | |
| | Brynn N Radtke | |
| P2860 | cites work | Expression of somatostatin and somatostatin receptor subtypes 1-5 in human normal and diseased kidney | Q30487782 |
| | Effects of somatostatin analog SOM230 on cell proliferation, apoptosis, and catecholamine levels in cultured pheochromocytoma cells | Q33337708 |
| | Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives. | Q33753449 |
| | Reducing polycystic liver volume in ADPKD: effects of somatostatin analogue octreotide | Q33827422 |
| | Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease | Q33979298 |
| | Mammalian target of rapamycin regulates vascular endothelial growth factor-dependent liver cyst growth in polycystin-2-defective mice. | Q34091331 |
| | Systemic distribution of somatostatin receptor subtypes in human: an immunohistochemical study | Q34562555 |
| | Somatostatin and Somatostatin Receptor Physiology | Q35117353 |
| | Molecular signaling of somatostatin receptors. | Q35778257 |
| | Inhibition of Cdc25A suppresses hepato-renal cystogenesis in rodent models of polycystic kidney and liver disease | Q36422436 |
| | Pre-clinical and clinical experiences with novel somatostatin ligands: advantages, disadvantages and new prospects | Q36454023 |
| | Morphological and functional features of hepatic cyst epithelium in autosomal dominant polycystic kidney disease | Q36559639 |
| | Characterization of the antiproliferative signal mediated by the somatostatin receptor subtype sst5. | Q36566036 |
| | Pasireotide (SOM230): development, mechanism of action and potential applications | Q36989087 |
| | Cholangiociliopathies: genetics, molecular mechanisms and potential therapies | Q37317821 |
| | Biological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomas | Q37815624 |
| | Somatostatin analogues for treatment of polycystic liver disease | Q37824573 |
| | Polycystic liver diseases: congenital disorders of cholangiocyte signaling | Q37868328 |
| | Expression of somatostatin receptors in human melanoma cell lines: effect of two different somatostatin analogues, octreotide and SOM230, on cell proliferation. | Q39741277 |
| | Expression of somatostatin receptors in normal and cirrhotic human liver and in hepatocellular carcinoma | Q40537154 |
| | SOM230: a new somatostatin peptidomimetic with potent inhibitory effects on the growth hormone/insulin-like growth factor-I axis in rats, primates, and dogs | Q44142791 |
| | Effects of somatostatin analogs on glucose homeostasis in rats | Q44680203 |
| | Inhibition of endothelial proliferation by the somatostatin analogue SOM230. | Q45097765 |
| | Effects of somatostatin analogs on a growth hormone-releasing hormone secreting bronchial carcinoid, in vivo and in vitro studies | Q46239530 |
| | Differential effects of octreotide and pasireotide on somatostatin receptor internalization and trafficking in vitro | Q46252964 |
| | Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease | Q46545498 |
| | The long-term outcome of patients with polycystic liver disease treated with lanreotide. | Q51490969 |
| | Epithelial expression of angiogenic growth factors modulate arterial vasculogenesis in human liver development. | Q51968770 |
| | Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3',5'-cyclic monophosphate. | Q53563592 |
| | Agonist-dependent regulation of cloned human somatostatin receptor types 1-5 (hSSTR1-5): subtype selective internalization or upregulation | Q71395008 |
| | sst2 somatostatin receptor mediates cell cycle arrest and induction of p27(Kip1). Evidence for the role of SHP-1 | Q77754899 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 409-421 | |
| P577 | publication date | 2013-03-06 | |
| P1433 | published in | Hepatology | Q15724398 |
| P1476 | title | Pasireotide is more effective than octreotide in reducing hepatorenal cystogenesis in rodents with polycystic kidney and liver diseases | |
| P478 | volume | 58 | |